Drozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells.Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.
In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody
Application Notes:
Applications: ELISA,neutralization,functional assays such as bioanalytical PK and ADA assays,and those assays for studying biological pathways. ResearchArea: Cancer immunology. Shipping: Ice Bag
* VAT and and shipping costs not included. Errors and price changes excepted
